{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:28:34Z","timestamp":1782905314211,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA115414"],"award-info":[{"award-number":["CA115414"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-08-135-01-CNE"],"award-info":[{"award-number":["RSG-08-135-01-CNE"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Carroll-Feist Predoctoral Fellowship Award"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302807"],"award-info":[{"award-number":["81302807"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013494","name":"West Light Foundation of The Chinese Academy of Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013494","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China and Yunnan Province","award":["U1402227"],"award-info":[{"award-number":["U1402227"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.bcp.2016.07.005","type":"journal-article","created":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T07:23:36Z","timestamp":1468049016000},"page":"39-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK"],"prefix":"10.1016","volume":"116","author":[{"given":"Hongyu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaowei","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingmei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhennan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shile","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2016.07.005_b0005","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0738-081X(91)90075-V","article-title":"Ciclopirox olamine: a hydroxypyridone antifungal agent","volume":"9","author":"Abrams","year":"1991","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.bcp.2016.07.005_b0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-4362.2001.01156.x","article-title":"Ciclopirox: an overview","volume":"40","author":"Gupta","year":"2001","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.bcp.2016.07.005_b0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1016-8478(23)13707-1","article-title":"The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae","volume":"15","author":"Leem","year":"2003","journal-title":"Mol. Cells"},{"key":"10.1016\/j.bcp.2016.07.005_b0020","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1128\/AAC.47.6.1805-1817.2003","article-title":"Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors","volume":"47","author":"Niewerth","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.07.005_b0025","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2009-03-209965","article-title":"Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells","volume":"114","author":"Eberhard","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2016.07.005_b0030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.23640","article-title":"Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies","volume":"89","author":"Minden","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcp.2016.07.005_b0035","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/ijc.25255","article-title":"The antitumor activity of the fungicide ciclopirox","volume":"127","author":"Zhou","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2016.07.005_b0040","first-page":"887","article-title":"Targeting the Wnt\/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model","volume":"25","author":"Kim","year":"2011","journal-title":"In Vivo"},{"key":"10.1016\/j.bcp.2016.07.005_b0045","doi-asserted-by":"crossref","first-page":"10140","DOI":"10.18632\/oncotarget.2471","article-title":"Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway","volume":"5","author":"Zhou","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2016.07.005_b0050","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ijc.10515","article-title":"The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro","volume":"100","author":"Clement","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2016.07.005_b0055","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1096\/fj.02-0586fje","article-title":"The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis","volume":"17","author":"Linden","year":"2003","journal-title":"Faseb J."},{"key":"10.1016\/j.bcp.2016.07.005_b0060","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/onc.2010.590","article-title":"The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway","volume":"30","author":"Luo","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2016.07.005_b0065","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.exphem.2013.04.012","article-title":"Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity","volume":"41","author":"Sen","year":"2013","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bcp.2016.07.005_b0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"MTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2016.07.005_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.06.017","article-title":"MTOR kinase inhibitors as potential cancer therapeutic drugs","volume":"340","author":"Sun","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2016.07.005_b0080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.drudis.2011.02.008","article-title":"Targeting the mTOR kinase domain: the second generation of mTOR inhibitors","volume":"16","author":"Zhang","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2016.07.005_b0085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev-pharmtox-010611-134537","article-title":"AMPK and mTOR in cellular energy homeostasis and drug targets","volume":"52","author":"Inoki","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2016.07.005_b0090","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.bcp.2016.07.005_b0095","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/BJ20081668","article-title":"MTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)","volume":"416","author":"Garcia-Martinez","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2016.07.005_b0100","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1158\/0008-5472.CAN-10-4058","article-title":"MTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways","volume":"71","author":"Gulhati","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2016.07.005_b0105","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","article-title":"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive","volume":"6","author":"Jacinto","year":"2004","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2016.07.005_b0110","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1038\/onc.2008.137","article-title":"Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins","volume":"27","author":"Liu","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2016.07.005_b0115","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bcp.2016.07.005_b0120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1471-4892(03)00071-7","article-title":"Targeting mTOR signaling for cancer therapy","volume":"3","author":"Huang","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bcp.2016.07.005_b0125","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2016.07.005_b0130","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2217\/fon.15.70","article-title":"Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review","volume":"11","author":"Huang","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.bcp.2016.07.005_b0135","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2016.07.005_b0140","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.cub.2003.10.031","article-title":"LKB1 is the upstream kinase in the AMP-activated protein kinase cascade","volume":"13","author":"Woods","year":"2003","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bcp.2016.07.005_b0145","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cmet.2014.09.013","article-title":"AMPK\u2013sensing energy while talking to other signaling pathways","volume":"20","author":"Hardie","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2016.07.005_b0150","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bcp.2016.07.005_b0155","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1097-2765(03)00220-X","article-title":"Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2","volume":"11","author":"Garami","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2016.07.005_b0160","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Inoki","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.bcp.2016.07.005_b0165","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ncb999","article-title":"Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins","volume":"5","author":"Zhang","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2016.07.005_b0170","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint","volume":"30","author":"Gwinn","year":"2008","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2016.07.005_b0175","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1073\/pnas.0608510104","article-title":"Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells","volume":"104","author":"Urano","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2016.07.005_b0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1476-4598-5-15","article-title":"Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions","volume":"5","author":"Yin","year":"2006","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2016.07.005_b0185","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/db07-0381","article-title":"Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP","volume":"57","author":"Kim","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2016.07.005_b0190","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1038\/sj.onc.1209691","article-title":"Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways","volume":"25","author":"Liu","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2016.07.005_b0195","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1593\/neo.05820","article-title":"CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR\/Hif-1alpha\/VEGF signaling","volume":"8","author":"Wan","year":"2006","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2016.07.005_b0200","doi-asserted-by":"crossref","first-page":"14424","DOI":"10.1074\/jbc.273.23.14424","article-title":"Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability","volume":"273","author":"Hashemolhosseini","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2016.07.005_b0205","doi-asserted-by":"crossref","first-page":"C281","DOI":"10.1152\/ajpcell.00422.2003","article-title":"G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K\/AKT\/mTOR\/p70S6K1 signaling in human ovarian cancer cells","volume":"287","author":"Gao","year":"2004","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bcp.2016.07.005_b0210","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1038\/sj.onc.1208471","article-title":"Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity","volume":"24","author":"Tirado","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2016.07.005_b0215","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2003-05-1543","article-title":"Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone","volume":"103","author":"Stromberg","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2016.07.005_b0220","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.humpath.2010.07.021","article-title":"Mammalian target of rapamycin regulates expression of beta-catenin in hepatocellular carcinoma","volume":"42","author":"Feng","year":"2011","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bcp.2016.07.005_b0225","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1593\/neo.111570","article-title":"Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression","volume":"14","author":"Luo","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2016.07.005_b0230","doi-asserted-by":"crossref","first-page":"36490","DOI":"10.1074\/jbc.M401208200","article-title":"Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity","volume":"279","author":"Huang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2016.07.005_b0235","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1593\/neo.08586","article-title":"Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK\/REDD1 signaling axis in head and neck squamous cell carcinoma","volume":"10","author":"Schneider","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2016.07.005_b0240","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.neulet.2004.03.073","article-title":"Activation of HIF-1alpha mRNA by hypoxia and iron chelator in isolated rat carotid body","volume":"363","author":"Roy","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2016.07.005_b0245","doi-asserted-by":"crossref","first-page":"13215","DOI":"10.1074\/jbc.M113.463679","article-title":"Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation","volume":"288","author":"Li","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2016.07.005_b0250","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2016.07.005_b0255","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","article-title":"Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor\/insulin receptor substrate-1\/phosphatidylinositol 3-kinase cascade","volume":"4","author":"Shi","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2016.07.005_b0260","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition","volume":"65","author":"Sun","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2016.07.005_b0265","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2016.07.005_b0270","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.1199498","article-title":"The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling","volume":"332","author":"Hsu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bcp.2016.07.005_b0275","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.1199484","article-title":"Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling","volume":"332","author":"Yu","year":"2011","journal-title":"Science"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216301708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216301708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T05:00:18Z","timestamp":1718686818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295216301708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":55,"alternative-id":["S0006295216301708"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2016.07.005","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2016.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}